VolitionRX Limited (VNRX) News

VolitionRX Limited (VNRX): $2.23

-0.12 (-5.11%)

POWR Rating

Component Grades













Filter VNRX News Items

VNRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VNRX News Highlights

  • VNRX's 30 day story count now stands at 5.
  • Over the past 15 days, the trend for VNRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • VET are the most mentioned tickers in articles about VNRX.

Latest VNRX News From Around the Web

Below are the latest news stories about VOLITIONRX LTD that investors may wish to consider to help them evaluate VNRX as an investment opportunity.

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on January 25, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-m

Yahoo | January 23, 2023

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition's Nu.Q® Vet commercial strategy.

Yahoo | January 20, 2023

Sidoti's January Micro-Cap Conference

Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.

Yahoo | January 17, 2023

Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. ("IDEXX") reference laboratory network in the U.S.

Yahoo | January 12, 2023

Volition Issues Business Review 2022

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations.

Yahoo | January 8, 2023

Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022

The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.

Yahoo | December 5, 2022

Maxim Group Remains a Buy on VolitionRX (VNRX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on VolitionRX (VNRX - Research Report) yesterday and set a price target of $5.00. The company's shares opened today at $1.98.According to TipRanks, McCarthy is an analyst with an average return of -37.8% and a 14.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.Currently, the analyst consensus on VolitionRX is a Moderate Buy with an average price target of $5.00.See today’s best-performing stocks on TipRanks >>Based on VolitionRX's latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32.

Ryan Adist on TipRanks | November 22, 2022

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2022. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Yahoo | November 14, 2022

Volition Announces Clinical Research Study with Oncovet

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Yahoo | November 14, 2022

Volition to Participate in a Lung Cancer Screening Study in France

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has been invited to participate in a government-backed prospective study to evaluate the performance of blood biomarkers in the early detection of lung cancer with Hospices Civils de Lyon ("HCL"), France's second largest university hospital.

Yahoo | November 10, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5882 seconds.